CatalystFDA/Bio

HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cance

Statistically significant survival improvements in MET-driven EGFR-mutated lung cancer post-TAGRISSO.

What changed

Statistically significant survival improvements in MET-driven EGFR-mutated lung cancer post-TAGRISSO.

Why it matters

Statistically significant survival improvements in MET-driven EGFR-mutated lung cancer post-TAGRISSO. — impact context not separately stored; see What changed.

Sources

eodhd